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The revolution will be open-source: how 3D bioprinting can 
change 3D cell culture
Robert D. Bruno, John Reid and Patrick C. Sachs
Comment on: Consistent and reproducible cultures of large-scale 3D mammary epithelial structures using an accessible bioprint-
ing platform by Reid et al. Breast Cancer Research. 2018; 20:122. https://doi.org/10.1186/s13058-018-1045-4
The development of three-dimensional culture 
scaffolds represents a revolutionary step forward for in 
vitro culture systems. Various synthetic and naturally 
occurring substrates have been developed that support 
3D growth of cells. In most fields, including mammary 
gland biology and tumorigenesis, the two most common 
substrates used are the basement membrane rich 
extracellur matrix (ECM) isolated from Engelbreth-
Holm-Swarm (EHS) mouse sarcomas (e.g. Matrigel) and 
collagen extracted from rat-tails. The processes of 3D 
culture in these two substrates has remained unchanged 
for nearly half a century: cells are either mixed with 
unpolymerized matrix to disperse them randomly 
throughout the substrate upon polymerization or overlaid 
randomly on top of a preformed hydrogel. While effective 
in generating organoid/tumoroid structures, the random 
nature of these processes has many drawbacks that limit 
the reproducibility and tunability of the experimental 
design. Furthermore, random cellular distributions limit 
the utility of these substrates for studying interactions 
within the cellular microenvironment, which have been 
shown to be critical for the control of stem and cancer cell 
function [1].
To overcome these issues, computer numerically 
controlled (CNC) devices can be adapted to precisely 
control cellular deposition within hydrogels. An example 
of these devices can be found in the three-axis control of 
modern 3D fusion deposition method (FDM) printers. 
Despite a rapid drop in cost of 3D printing technology, 
printers specifically engineered for bioprinting purposes 
generally remain unattainably expensive for general 
biological research laboratories. Thus the technology 
has been limited to specific biofabrication applications 
in specialty biomedical engineering laboratories. 
Furthermore, commercially available bioprinters 
are exclusively designed for printing “bioinks” 
(unpolymerized scaffoldings with or without cells) into 
shapes. While potentially useful for medical reconstructive 
procedures, the shape of the hydrogel is meaningless to 
cell biologists seeking to understand basic questions of 
cell biology, or for engineering applications seeking to 
direct specific differentiation of cells. 
To this end, we recently developed a low-cost open 
access 3D bioprinting system that can be used for scientists 
applications (Figure 1) [2]. The printer is an open source 
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Figure 1: Custom benchtop 3D bioprinter and its 
application for printing large mammary organoids. 
Top: Image of an example 3D bioprinter constructed off of the 
Felix 3.0 (FELIXrobotics, NL) platform. Middle: Example of 
coordinated print of clusters of red fluorescent protein (RFP) 
labeled MCF12a cells at distances of 200µm in linear array. 
Image taken 24 hours post-print. Scale bar = 200µm. Bottom: 
Mature organoid (21 days post-print) formed from coordinated 
print of clusters of RFP MCF12a cells into a circular array. 
Resulting organoids have been shown to have contiguous lumens 
stretching > 3mm in length.
Oncotarget4725www.oncotarget.com
project that allows other laboratories to build their own 
system. Initially, all necessary parts can be printed using a 
standard off-the-shelf 3D FDM printer. The same printer 
can then be modified with these parts into a 3D bioprinter. 
In essence, you can 3D print your own 3D bioprinter. This 
system is designed to be adaptable to any application the 
end user requires, and we have described its use for both 
printing cells as well as guiding electrodes for directed 
electrical pulsing of cells [3, 4]. To increase precision 
and maintain integrity of printed cells, we use pulled 
glass micropipette syringes as our cell injection “print-
head” [2]. Compared to standard steel needles attached to 
luer lock syringes, these glass micropipettes have a finer 
point and reduce sheer force on the cells. Combined, this 
minimizes disruptions to the cells and allows the hydrogel 
to seal behind the print. Thus, our system allows for the 
precise placement of cells, that then self-organize into 
organoids/tumoroids, making functional structures [4]. 
This differs from many bioprinting approaches that print 
cell free or cell-laden “bioinks” into 3D shapes. Again, 
while these approachees are potentially useful for specific 
medical reconstruction procedures, they have little utility 
for most biological applications. For example, cells printed 
in the shape of a mammary gland are not a mammary 
gland; it is the coordinated function and differentiation of 
cells through development that make tissues and organs 
functional. 
We have recently described the use of this system 
for printing mammary organoids in standard 3D hydrogels 
[4]. By depositing specific numbers of cells at controllable 
distances we could guide the growth of organoids into 
predictable sizes and shapes (Figure 1). The key to the 
guided growth was the fact that mammary epithelial 
cells (MCF12a and MCF10a) would preferentially grow 
towards neighboring prints, forming single contiguous 
organoids. Using this strategy, we generated large 
contiguous luminal mammary organoids (> 5mm in 
length). This is in clear contrast to random culture where 
the dispersion of cells results in random organoid shape 
and size, with organoids never forming more than a couple 
of hundred microns in size. Controlling for organoid 
distancing, shaping, and sizing is thus not feasible in 
standard culture models and therefore interpretation 
of studies where these factors may play a role becomes 
difficult. This is particularly true for experiments on 
microenvironmental forces and cancer/epithelial cell 
growth. Because surrounding organoids can influence the 
rigidity of the microenvironment, control of the placement, 
spacing, and size is critical. 
In an era of poor data reproducibility in science 
[5], instruments and methods designed to limit lab-to-
lab variability are in need. The open source nature of our 
bioprinter helps facilitate standardization of experimental 
parameters across laboratories. This is because the 
machine instructions or GCODE generated for printing 
experiments can be shared once data is published. We have 
shared our files through our website www.odustemcell.
org. Researchers can go to this website, download the 
files needed to print their own bioprinter, and then use the 
GCODE files necessary to repeat our experiments exactly 
using their own bioprinter. While this certainly doesn’t 
eliminate all inter-laboratory variability, it helps simplify 
the process of reproducing an experiment. 
Our current focused application of this printing 
technology is to understand the role of the cellular 
microenvironment in controlling differentiation of stem 
and cancer cells (Reid et al., Submitted). We have explored 
this topic in in vivo models [6–10], but our bioprinting 
platform allows for mechanistic insights into the process. 
These studies are ongoing, but one can imagine our 
printing platform can be used to improve any application 
where the random nature of traditional 3D culture is a 
confounding variable. And, one could argue, nearly every 
study is potentially confounded by this factor. 
A common issue with modern science/scientist is the 
tendency to assign radical ideas to the “science fiction” 
classification; however, bioprinting needs not be the stuff 
of science fiction. Our studies highlight the ease of access 
and the utility of the technology for basic cell and cancer 
biology studies. Thus, we hope to lower the bar of entry 
further by developing easier-to-access solutions, such 
as ready built kits, and a graphic user interface (GUI) to 
simplify the experimental programming. The system offers 
a potentially revolutionary step forward for 3D culture 
models of development and cancer. 
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